ID   MBA72
AC   CVCL_A2FY
SY   Mba72
DR   cancercelllines; CVCL_A2FY
DR   Wikidata; Q105510037
RX   DOI=10.1186/1479-5876-12-S1-P7;
RX   PubMed=25623468;
RX   PubMed=27540956;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=25623468).
CC   Sequence variation: Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Val92Met (c.274G>A); ClinVar=VCV000014308; Zygosity=Heterozygous (PubMed=27540956).
CC   Sequence variation: Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=27540956).
CC   Miscellaneous: Age/sex of donor and metastatic site from personal communication of Guida, Gabriella.
CC   Derived from site: Metastatic; Right temple; UBERON=UBERON_8480027.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   82Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   DOI=10.1186/1479-5876-12-S1-P7;
RA   Azzariti A., Porcelli L., Quatrale A.E., Sidella L., Iacobazzi R.M.,
RA   Guida G., Maida I., Cocco T., Ferretta A., Strippoli S., Guida S.,
RA   Tommasi S., Paradiso A., Guida M.;
RT   "Barasertib: a novel approach for the treatment of metastatic melanoma.";
RL   J. Transl. Med. 12 Suppl. 1:P7-P7(2014).
//
RX   PubMed=25623468; DOI=10.1186/s12967-015-0385-4; PMCID=PMC4314759;
RA   Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L., Maida I.,
RA   Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S.,
RA   Tommasi S., Guida M., Azzariti A.;
RT   "Aurora kinase B inhibition reduces the proliferation of metastatic
RT   melanoma cells and enhances the response to chemotherapy.";
RL   J. Transl. Med. 13:26.1-26.13(2015).
//
RX   PubMed=27540956; DOI=10.1111/pcmr.12516;
RA   Guida M., Strippoli S., Ferretta A., Bartolomeo N., Porcelli L.,
RA   Maida I., Azzariti A., Tommasi S., Grieco C., Guida S., Albano A.,
RA   Lorusso V., Guida G.;
RT   "Detrimental effects of melanocortin-1 receptor (MC1R) variants on the
RT   clinical outcomes of BRAF V600 metastatic melanoma patients treated
RT   with BRAF inhibitors.";
RL   Pigment Cell Melanoma Res. 29:679-687(2016).
//